Morningstar

Ipsen SA IPN

Morningstar Rating
Unlock
Stock XPAR Rating as of
€140.60 −1.50 (1.06%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Narrow-Moat Ipsen's Portfolio Expansion Efforts Add Value as Somatuline Faces Generic Pressure

Rachel Elfman

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. The company has a global footprint and sells more than 20 drugs in 115 countries, and it has a direct commercial presence in 34 countries. Over the past nearly 100 years, the company has shifted its focus to specialty care products and away from its legacy consumer healthcare segment.

Read Analysis

Price vs Fair Value

View History
IPN is trading at a LOCK|Rs#?yT premium.
Price
€140.60
Fair Value
LOCK|n!
Uncertainty
LOCK|$@<m%
1-Star Price
LOCK|y.T!>
5-Star Price
LOCK|g.wX
Economic Moat
LOCK|FCM^!
Capital Allocation
LOCK|bQS#F>

Bulls Say, Bears Say

Bulls

Ipsen has a sound financial structure and strong cash generation, which allows it to further develop and expand its pipeline.

Bears

Many of Ipsen’s products are facing competitive pressures from lower-priced generics.

Show More

News

View All

Trading Information

Previous Close Price
€142.10
Day Range
€140.40–143.40
52-Week Range
€112.70–174.00
Bid/Ask
€140.30 / €0.00
Shares Outstanding
82.45M
Market Cap
€11.59B
Volume/Avg
104,670 / 102,447

Key Statistics

Price/Earnings (Normalized)
11.36
Price/Sales
2.72
Dividend Yield (Trailing)
1.14%
Dividend Yield (Forward)
1.14%
Dividend Payment Schedule
Jun
Total Yield
1.78%

Company Profile

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Core
Total Number of Employees
5,535
Website
https://www.ipsen.com

Competitors

Valuation

View More
Metric
IPN
JAZZ
UCB
Price/Earnings (Normalized)
 11.369.5416.84
Price/Book Value
 2.473.143.29
Price/Sales
 2.723.264.58
Price/Cash Flow
 8.888.7716.05
Price/Earnings
IPN
JAZZ
UCB

Financial Strength

Metric
IPN
JAZZ
UCB
Quick Ratio
 1.761.380.82
Current Ratio
 1.971.781.20
Interest Coverage
 15.245.2627.73
Quick Ratio
IPN
JAZZ
UCB

Profitability

Metric
IPN
JAZZ
UCB
Return on Assets (Normalized)
 15.69%16.01%13.57%
Return on Equity (Normalized)
 25.09%42.74%23.59%
Return on Invested Capital (Normalized)
 21.65%20.79%19.03%
Return on Assets
IPN
JAZZ
UCB

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|lq^?^T&LOCK|#<J>$66B
 Teva Pharmaceutical Industries Ltd
TEVA
LOCK|wt$y&r@LOCK|<Shd$46B
 Haleon PLC ADR
HLN
LOCK|JKXhbcLOCK|!bl$38B
 Zoetis Inc Class A
ZTS
LOCK|$#>b<xpLOCK|$&$29B
 Viatris Inc
VTRS
LOCK|yDKwhm?LOCK|>m?$20B
 Elanco Animal Health Inc
ELAN
LOCK|RZfLOCK|&$$11B
 Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|>cLYp&LOCK|crb$10B
 Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|t&#R?PSLOCK|>#$7B
 Prestige Consumer Healthcare Inc
PBH
LOCK|F#&C<qQLOCK|#$Yd$2B
 Perrigo Co PLC
PRGO
LOCK|mm$PccLOCK|S$$2B

Sponsor Center